"Such genes will be quickly selected in males because new beneficial mutations will be quickly apparent".
While some mutations will be common drivers of disease, the genetic faults that cause cancer in one patient may look very different to those in another.
Nevertheless, said Dr. Walsh, "it's safe to say that a large proportion of those mutations will be benign".
Most of the mutations will be deleterious.
Thus, if the DNA damage is not repaired correctly, mutations will be induced and may initiate the development of CRC.
Some regulatory element mutations will be associated with phenotypes distinct from any identified for coding-region mutations.
Vogelstein predicts that most new driver mutations will be rare; and nearly all will be part of same 12 pathways.
If the hourglass model applies to vertebrate development, then the effects of these mutations will be greatest at mid-development, representing the constricted portion of the hourglass.
Most of the spontaneous mutations are neutral or deleterious, while disadvantage mutations will be discarded, and neutral mutations can still retain.
Rare mutations will be difficult to catalogue comprehensively [10].
Moreover, use of ARs harboring patient-related mutations will be amenable to agonist/antagonist screening for personalized patient drug selection.
